Company Overview and News
Stop missing out on important events!
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced a reserved capital increase of ordinary shares of the Company to a specific category of investors. The gross proceeds from the financing are €26.25 million, for a total of 3,500,000 new ordinary shares (the "New Shares"). (0-1)
ReportsnReports.com adds "Duchenne Muscular Dystrophy - Pipeline Review, H1 2017" to its store providing comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
If Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were any other company, most likely the market would dismiss the whole thing, confident the problem would be readily resolved. When the gaffe is dished out by a beleaguered Valeant, though, every other painful misstep the company has made over the course of the past year is remembered. And VRX stock suffers more than it arguably should simply because of its marred reputation.
SOPHIA ANTIPOLIS, France, July 5, 2016 (GLOBE NEWSWIRE) -- Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced an agreement with GHO Capital, a European specialist investor in healthcare, to transfer its European and International commercial operations, for a value of up to EURO26 million, to a newly-founded private company focused on the commercialisation of a portfolio of ophthalmic products in Europe.